Tailoring Tfh profiles enhances antibody persistence to a clade C HIV-1 vaccine in rhesus macaques
Anil Verma,
Chase E Hawes,
Sonny R Elizaldi,
Justin C Smith,
Dhivyaa Rajasundaram,
Gabriel Kristian Pedersen,
Xiaoying Shen,
LaTonya D Williams,
Georgia D Tomaras,
Pamela A Kozlowski,
Rama R Amara,
Smita S Iyer
Affiliations
Anil Verma
Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, United States
Chase E Hawes
Graduate Group in Immunology, University of California, Davis, Davis, United States; California National Primate Research Center, University of California, Davis, Davis, United States
Sonny R Elizaldi
Graduate Group in Immunology, University of California, Davis, Davis, United States; Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, United States
Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, United States
Dhivyaa Rajasundaram
Bioinformatics Core, Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, United States
Gabriel Kristian Pedersen
Statens Serum Institute, Copenhagen, Denmark
Xiaoying Shen
Center for Human Systems Immunology, Durham, United States; Department of Surgery, Duke University Medical Center, Durham, United States; Duke Human Vaccine Institute, Duke University Medical Center, Durham, United States
LaTonya D Williams
Center for Human Systems Immunology, Durham, United States; Department of Surgery, Duke University Medical Center, Durham, United States; Duke Human Vaccine Institute, Duke University Medical Center, Durham, United States
Georgia D Tomaras
Center for Human Systems Immunology, Durham, United States; Department of Surgery, Duke University Medical Center, Durham, United States; Duke Human Vaccine Institute, Duke University Medical Center, Durham, United States; Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, United States; Department of Integrative Immunobiology, Duke University Medical Center, Durham, United States
Pamela A Kozlowski
Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, United States
Rama R Amara
Department of Microbiology and Immunology, Emory University, Atlanta, United States; Yerkes National Primate Research Center, Emory University, Atlanta, United States
Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, United States; California National Primate Research Center, University of California, Davis, Davis, United States; Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, United States
CD4 T follicular helper cells (Tfh) are essential for establishing serological memory and have distinct helper attributes that impact both the quantity and quality of the antibody response. Insights into Tfh subsets that promote antibody persistence and functional capacity can critically inform vaccine design. Based on the Tfh profiles evoked by the live attenuated measles virus vaccine, renowned for its ability to establish durable humoral immunity, we investigated the potential of a Tfh1/17 recall response during the boost phase to enhance persistence of HIV-1 Envelope (Env) antibodies in rhesus macaques. Using a DNA-prime encoding gp160 antigen and Tfh polarizing cytokines (interferon protein-10 (IP-10) and interleukin-6 (IL-6)), followed by a gp140 protein boost formulated in a cationic liposome-based adjuvant (CAF01), we successfully generated germinal center (GC) Tfh1/17 cells. In contrast, a similar DNA-prime (including IP-10) followed by gp140 formulated with monophosphoryl lipid A (MPLA) +QS-21 adjuvant predominantly induced GC Tfh1 cells. While the generation of GC Tfh1/17 cells with CAF01 and GC Tfh1 cells with MPLA +QS-21 induced comparable peak Env antibodies, the latter group demonstrated significantly greater antibody concentrations at week 8 after final immunization which persisted up to 30 weeks (gp140 IgG ng/ml- MPLA; 5500; CAF01, 2155; p<0.05). Notably, interferon γ+Env-specific Tfh responses were consistently higher with gp140 in MPLA +QS-21 and positively correlated with Env antibody persistence. These findings suggest that vaccine platforms maximizing GC Tfh1 induction promote persistent Env antibodies, important for protective immunity against HIV.